GSK/$GSK

13:30
21:10
04:45
12:25
20:00
1D1W1MYTD1Y5YMAX

About GSK

In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.

Ticker

$GSK

Primary listing

NYSE

Industry

Pharmaceuticals

Employees

68,629

ISIN

US37733W2044

GSK Metrics

BasicAdvanced
$78B
37.32
$1.04
0.27
$1.53
4.36%

What the Analysts think about GSK

Analyst ratings (Buy, Hold, Sell) for GSK stock.

Bulls say / Bears say

GSK announced a $2.5 billion share buyback and raised its long-term sales target to nearly $50 billion, driven by strong performance in HIV and cancer drug sales. (reuters.com)
Berenberg reaffirmed its Buy rating on GSK stock, maintaining the price target at £18.20, citing confidence in the company's strategic progress in HIV treatments. (investing.com)
GSK reported a 35% year-on-year increase in consolidated profit for its Indian subsidiary, driven by strong demand for respiratory drugs and the antibiotic Augmentin. (reuters.com)
UBS downgraded GSK's stock rating from Buy to Neutral, adjusting the price target to £15.80 from £20.40, citing revised expectations for the company's products and financial performance. (investing.com)
Hedge fund Citadel took a short position in GSK, amounting to 305 million pounds, indicating a bet that the company's stock will decline. (reuters.com)
GSK reached agreements to settle U.S. state court Zantac product liability cases for up to $2.2 billion, which could impact the company's financial position. (financecharts.com)
Data summarised monthly by Lightyear AI. Last updated on 7 Jun 2025.

GSK Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

GSK Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $GSK

Sign up or log in to buy
Capital at risk
Market openADR

Upcoming events

Jul10
GSK
Dividend·Payment
$0.429088Per share
FAQs